1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial

Viking Therapeutics thought it was running a phase 1b clinical trial. The FDA thought otherwise, leading it to slap a clinical hold on the metabolic disorder study while Viking does the preclinical work needed to enter phase 2.